María Victoria
Mateos Manteca
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublications in collaboration with researchers from Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (44)
2024
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
2022
-
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
British Journal of Haematology, Vol. 199, Núm. 3, pp. 344-354
2021
-
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507
-
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
HemaSphere, Vol. 5, Núm. 2
2020
-
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
Blood Cancer Journal, Vol. 10, Núm. 10
-
Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT
Bone Marrow Transplantation
-
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
Bone Marrow Transplantation, Vol. 55, Núm. 2, pp. 419-430
-
FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
2019
-
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
Blood
-
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712
-
Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
Blood Cancer Journal, Vol. 9, Núm. 12
2018
-
A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: Biological and clinical utility
Haematologica, Vol. 103, Núm. 5, pp. 880-889
2017
-
Amiloride, an old diuretic drug, is a potential therapeutic agent for multiple myeloma
Clinical Cancer Research, Vol. 23, Núm. 21, pp. 6602-6615
-
DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
Journal of Hematology and Oncology, Vol. 10, Núm. 1
2015
-
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
British Journal of Haematology, Vol. 170, Núm. 6, pp. 804-813
-
Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma
Haematologica
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300